Associated Papers
Updated global prevalence and ethnic diversity of von Willebrand disease based on population genetics analysis.
Seidizadeh O et al.
Scientific Reports, 2026
Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis.
Kalot MA et al.
Blood Advances, 2022
Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
Michiels JJ et al.
Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/hemostasis, 2017
A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct.
Lynch CJ et al.
Plos One, 2017
C1272F: a novel type 2A von Willebrand's disease mutation in A1 domain; its clinical significance.
Woods AI et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia, 2012
Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease.
Dong J et al.
Plos One, 2012
[Gene mutation analysis of one case with von willebrand disease type 2A].
Hou LH et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2009
L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
Kashiwagi T et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia, 2008
Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations.
O'Brien LA et al.
Journal of Thrombosis and Haemostasis : Jth, 2005
Type 2 A (group II) von Willebrand disease mutations increase the susceptibility of VWF to ADAMTS-13.
Tsai HM
Journal of Thrombosis and Haemostasis : Jth, 2004
Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.
Sutherland JJ et al.
Journal of Molecular Modeling, 2004
A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.
O'Brien LA et al.
Journal of Thrombosis and Haemostasis : Jth, 2004